Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
- The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 08/05/2024
|
Avadel Pharmaceuticals to Join Russell 3000® Index
- DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
- 06/27/2024
|
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
- DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- 05/30/2024
|
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
- – 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –
- 05/22/2024
|
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
- DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA.
- 05/21/2024
|
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
- -- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy --
- 05/08/2024
|
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
- DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.
- 05/01/2024
|
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 04/29/2024
|
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
- Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges.
- 04/02/2024
|
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
- DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET.
- 04/01/2024
|
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
- DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- 03/05/2024
|
Avadel Pharmaceuticals Issues Statement On Patent Litigation
- DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™.
- 03/04/2024
|
Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript
- Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2023 Earnings Conference Call March 4, 2024 7:30 AM ET Company Participants Austin Murtagh - Stern IR Gregory Divis - CEO Richard Kim - Chief Commercial Officer Thomas McHugh - CFO Conference Call Participants Francois Brisebois - Oppenheimer Ami Fadia - Needham Andrew Tsai - Jefferies David Amsellem - Piper Sandler Ashwani Verma - UBS Myriam Belghiti - LifeSci Capital Chase Knickerbocker - Craig-Hallum Rudy Li - Leerink Matt Kaplan - Ladenburg Thalmann Oren Livnat - H.C. Wainwright Operator Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Call.
- 03/04/2024
|
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- -- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31 st , greater than 2,200 patients enrolled in RYZUP TM and more than 1,200 patients initiated therapy --
- 03/04/2024
|
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
- Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential for Lumryz to be pulled from the market. Lumryz can capture a significant portion of the narcolepsy market and expand into idiopathic hypersomnia.
- 01/28/2024
|
Here's Why You Should Invest in Avadel (AVDL) Stock Now
- Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
- 01/18/2024
|
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
- Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/15/2024
|
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
- The consensus price target hints at a 37.4% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 01/15/2024
|
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
- Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 01/12/2024
|
Avadel May Continue To Outperform With Positive Launch Momentum
- Avadel Pharma's launch of its product LUMRYZ is expected to drive the company's stock performance. LUMRYZ appears to have momentum and is differentiated from current narcolepsy treatments. The potential revenue for Avadel from LUMRYZ could ultimately range from $500 million to $2 billion, depending on market share and expansion into new indications.
- 01/11/2024
|
Avadel Pharmaceuticals PLC (AVDL) Q3 2023 Earnings Call Transcript
- Avadel Pharmaceuticals PLC (NASDAQ:AVDL ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Austin Murtagh - Stern Investor Relations Gregory Divis - CEO & Director Richard Kim - Chief Commercial Officer Jennifer Gudeman - SVP, Medical & Clinical Affairs Thomas McHugh - SVP & CFO Conference Call Participants Ami Fadia - Needham & Company Rudy Li - Leerink Partners Matthew Kaplan - Ladenburg Thalmann & Co. Francois Brisebois - Oppenheimer Chase Knickerbocker - Craig-Hallum David Amsellem - Piper Sandler & Co. Operator Greetings, and welcome to the Avadel Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions].
- 11/08/2023
|
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- -- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUP TM and more than 400 patients initiating therapy as of September 30 --
- 11/08/2023
|
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023
- – 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option –
- 10/20/2023
|
Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
- DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Biotech CNS/Neuro Summit on Thursday, October 12 at 9:00 a.m. ET.
- 10/05/2023
|
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
- DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- 08/31/2023
|
Avadel Pharmaceuticals: A Resilient Buy; A Comprehensive Assessment Of Potential Prospects
- Avadel's Q2 2023 earnings report shows promising growth and FDA endorsement of Lumryz for narcolepsy treatment. Lumryz has seen positive commercialization with high prescriber enrollments and reimbursement successes. Avadel presents potential growth avenues in exploring new markets and maintains a robust financial position.
- 08/21/2023
|
Avadel Pharmaceuticals plc (AVDL) Q2 2023 Earnings Call Transcript
- Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Austin Murtagh - Stern Investor Relations Gregory Divis - Chief Executive Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Senior Vice President, Medical and Clinical Affairs Thomas McHugh - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Andrew Tsai - Jefferies Ami Fadia - Needham & Company Marc Goodman - Leerink Matthew Kaplan - Ladenburg Thalmann Chase Knickerbocker - Craig Hallum Myriam Belghiti - LifeSci Capital Operator Greetings, and welcome to Avadel Pharmaceuticals Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
- 08/09/2023
|
Avadel Pharmaceuticals: Winning Is Sweet
- Avadel Pharmaceuticals plc finally won approval of Lumryz™ (sodium oxybate), despite cutthroat opposition from Jazz Pharmaceuticals plc. Potential sales estimate is $3bn. Avadel Pharmaceuticals is flying high, as it well should, but I am a buyer on dips.
- 07/20/2023
|
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
- DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 1:00 p.m. ET.
- 06/01/2023
|
Why Shares of Avadel Soared This Week
- Avadel said it plans to launch its lead therapy to treat excessive daytime sleepiness in adults with narcolepsy, in early June. The company had no revenue in the first quarter.
- 05/05/2023
|
Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch
- Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch
- 04/19/2023
|
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
- DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference on Monday, April 17 at 9:30 a.m. ET.
- 04/10/2023
|
Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call Transcript
- Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Officer Jennifer Gudeman – Senior Vice President-Medical and Clinical Affairs Richard Kim – Chief Commercial Officer Tom McHugh – Chief Financial Officer Conference Call Participants Chris Howerton – Jefferies Adam Evertts – LifeSci Capital David Amsellem – Piper Sandler Matt Kaplan – Ladenburg Thalmann Operator Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations.
- 03/31/2023
|
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
- DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2022.
- 03/29/2023
|
Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For Lumryz
- Avadel Pharmaceuticals' Lumryz has the potential to transform the narcolepsy treatment market. Avadel estimates that the total potential patient population for Lumryz could be greater than 30,000, with a market opportunity of over $3.0 billion annually.
- 03/12/2023
|
Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
- DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 1:00 p.m. ET.
- 02/08/2023
|
Avadel: Lumryz Overhang Now Removed, Rate Buy
- Lumyrz overhang now removed with competitor ordered to delist patent from FDA's Orange Book. The treatment has potential to create a remedial breakthrough in narcolepsy.
- 12/07/2022
|
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
- DUBLIN, Ireland, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- 11/22/2022
|
Avadel Pharmaceuticals plc (AVDL) Q3 2022 Earnings Call Transcript
- Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Ami Fadia - Needham Chris Howerton - Jefferies Adam Evertts - LifeSci Capital Marc Goodman - SVB Matt Kaplan - Ladenburg Thalmann Chase Knickerbocker - Craig Hallum Operator Good morning. My name is Rob and I will be your conference operator today.
- 11/09/2022
|
Avadel's LUMRYZ: A Good Night's Sleep For Narcolepsy Patients
- Avadel Pharmaceuticals' LUMRYZ (FT218), with its essential once daily dosing, has snagged a tentative approval from the FDA. Once finally approved, LUMRYZ has serious prospects for knocking off Jazz's flawed blockbuster XYREM/XYWAV duopoly.
- 09/06/2022
|
Avadel Pharmaceuticals: Navigating Through The Uncertainty
- Avadel Pharmaceuticals goes into the spotlight today. This small biopharma company recently got 'tentative' FDA approval for its flagship drug but is still waiting on one patent challenge to move forward to commercialization.
- 09/05/2022
|
Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2022 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Oren Livnat - H.C. Wainwright David Amsellem - Piper Sandler Adam Evertts - LifeSci Capital Chase Knickerbocker - Craig Hallum Operator Greetings, and welcome to Avadel Pharmaceuticals' Second Quarter 2020 Earnings Call.
- 08/09/2022
|
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
- DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, August 9, 2022, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2022.
- 08/02/2022
|
Avadel Cuts Workforce, Optimizes Cost Structure To Support This
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) announced its steps to explore every available pathway to accelerate the FDA approval of its lead drug candidate, FT218, before June 2023. Avadel has received and agreed upon what is expected to be a final label and is completing.
- 06/30/2022
|
Avadel: Further Delay, But Some Light At The End Of The Tunnel
- AVDL's FT218 is going to get delayed further over a patent issue. However, there's a goalpost in sight now, and the date is June 2023.
- 06/16/2022
|
How to Make Money With Penny Stocks in June, 3 Tips
- What you need to know about trading penny stocks right now The post How to Make Money With Penny Stocks in June, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/30/2022
|
Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR
- Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/27/2022
|
Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
- DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25 at 8:30 a.m. E.T.
- 05/18/2022
|
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval
- Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. FT218 is once nightly sodium oxybate for narcolepsy, which would compete with Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) twice-nightly franchise.
- 05/11/2022
|
Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Douglas Williamson - Chief Medical Officer Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Marc Goodman - SVB Securities Oren Livnat - H.C. Wainwright Matt Kaplan - Laddenburg Robin Garner - Craig Hallum Adam Evertts - LifeSci Capital Operator Ladies and gentlemen, thank you for standing by and welcome to the Avadel Pharmaceuticals' First Quarter 2022 Earnings Call.
- 05/09/2022
|
Why Avadel Pharmaceuticals Stock Is Skyrocketing Today
- The stock is rebounding from Monday's sell-off after a public statement from the company.
- 04/26/2022
|
Hot Penny Stocks to Buy Today? 3 For Your Watchlist
- Here's what you need to know about trading penny stocks on April 26th The post Hot Penny Stocks to Buy Today? 3 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/26/2022
|
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
- DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:
- 03/22/2022
|
Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
- We are initiating AVDL at a speculative buy rating, with a target price of USD 14.
- 03/21/2022
|
Avadel Pharmaceuticals plc's (AVDL) CEO Gregory Divis on Q4 2021 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc's (AVDL) CEO Gregory Divis on Q4 2021 Results - Earnings Call Transcript
- 03/17/2022
|
Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
- DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17 at 10:40 a.m. ET.
- 03/10/2022
|
Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
- DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 1:40 p.m. ET.
- 02/10/2022
|
Do Options Traders Know Something About Avadel (AVDL) Stock We Don't?
- Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.
- 12/08/2021
|
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
- DUBLIN, Ireland, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:
- 11/22/2021
|
Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q3 2021 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 8th
- DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2021.
- 11/01/2021
|
Avadel Pharmaceuticals: I Am Holding
- Avadel Pharmaceuticals: I Am Holding
- 10/31/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avadel Pharmaceuticals plc - AVDL
- New York, New York--(Newsfile Corp. - October 18, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avadel Pharmaceuticals plc ("Avadel" or the "Company") (NASDAQ: AVDL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avadel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 10/18/2021
|
Why Shares of Avadel Are Sinking Today
- A key regulatory decision is overdue, leaving shareholders to wonder when it might arrive.
- 10/18/2021
|
Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy
- DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug Administration (FDA) notified the company that the review of the New Drug Application (NDA) for FT218 is still ongoing, and action will likely not be taken in October. The FDA informed the company that there are no information requests at this time and a new target action date will be provided as soon as possible.
- 10/15/2021
|
Implied Volatility Surging for Avadel (AVDL) Stock Options
- Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.
- 09/29/2021
|
Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP
- DUBLIN, Ireland, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today the publication of data from its pivotal Phase 3 REST-ON trial of FT218 in SLEEP, the journal of the Sleep Research Society. The paper, titled “Once-Nightly Sodium Oxybate (FT218) Demonstrated Improvement of Symptoms in a Phase 3 Randomized Clinical Trial in Patients With Narcolepsy,” can be accessed at https://academic.oup.com/sleep/advance-article/doi/10.1093/sleep/zsab200/6343406?searchresult=1.
- 08/16/2021
|
Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2021 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
- DUBLIN, Ireland, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2021.
- 08/09/2021
|
Avadel Pharmaceuticals, The Jazz-Killer
- Avadel's once-nightly FT218 improves considerably over Xyrem's twice-nightly dosing.
- 08/05/2021
|
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
- DUBLIN, Ireland, July 07, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Wednesday, July 14 at 11:00 a.m. ET.
- 07/07/2021
|
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
- Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
- 06/02/2021
|
Avadel Pharmaceuticals - A Compelling Buy
- Avadel Pharmaceuticals - A Compelling Buy
- 05/14/2021
|
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2021 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results
- DUBLIN, Ireland, May 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, today provided a corporate update and announced its financial results for the first quarter ended March 31, 2021.
- 05/10/2021
|
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
- DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 10, 2021, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2021.
- 04/29/2021
|
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
- DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-SXB) for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the presentation of positive secondary endpoint data at the 2021 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 17-22, 2021. FT218 is currently under review at the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) target date of October 15, 2021.
- 04/17/2021
|
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2020 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2020 Results - Earnings Call Transcript
- 03/09/2021
|
Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
- FT218 assigned PDUFA target action date of October 15, 2021 FT218 assigned PDUFA target action date of October 15, 2021
- 03/01/2021
|
Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th
- DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021, to provide a company update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2020.
- 02/23/2021
|
Avadel Pharmaceuticals: Looking Good For Investors And Patients With Narcolepsy
- Avadel's flagship compound, FT218, is on its way towards approval with the FDA. FT218 once nightly dose has been proven more efficient and better accepted by patients than competing products.
- 02/10/2021
|
Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
- DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24th to 26th.
- 02/10/2021
|
3 Fast-Growing Small Caps to Consider
- Investors who target growth may want to consider the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.
- 12/13/2020
|
Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs
- DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the appointment of Dr. Jennifer Gudeman to the newly formed role of Vice President, Medical and Clinical Affairs, effective immediately. In this role her responsibilities will include overseeing all medical and clinical affairs activities, including the company's lead program, once-nightly FT218.
- 12/07/2020
|
Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences
- DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the Stifel Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference that are being held in November 2020.
- 11/11/2020
|
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Avadel Pharmaceuticals plc's (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc's (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program
- DUBLIN, Ireland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.
- 11/09/2020
|
Avadel (AVDL) Surges: Stock Moves 7.8% Higher
- Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- 08/18/2020
|
IPO Update: Harmony Biosciences Seeks $100 Million IPO (Pending:HRMY)
- Harmony Biosciences intends to raise $100 million in an IPO. The firm is developing and commercializing treatments for narcolepsy and related conditions.
- 08/11/2020
|
Avadel Pharmaceuticals plc (AVDL) Q2 2020 Earnings Call Transcript
- Thank you, Mr. McHugh, you may begin. As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
- 08/11/2020
|
Avadel Pharmaceuticals (AVDL) Received its Third Buy in a Row - Markets
- After Leerink Partners and Oppenheimer gave Avadel Pharmaceuticals (NASDAQ: AVDL) a Buy rating last month, the company received another Buy,
- 08/10/2020
|
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q2 2020 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q2 2020 Earnings Conference Call August 10, 2020 08:30 ET Company Participants Thomas McHugh - Chief Financial Officer Greg Divis - Chief Executive Officer Jordan Dubow - Chief Medical Officer Conference Call Participants Ami Fadia - Leerink Paul Matteis - Stifel Francois Brisebois - Craig-Hallum Capital Group David Amsellem - Piper Jaffray Presentation Operator Greetings, and welcome to the Avadel Pharmaceuticals Second Quarter 2020 Earnings Conference Call.
- 08/10/2020
|
Recap: Avadel Pharmaceuticals Q2 Earnings
- Shares of Avadel Pharmaceuticals (NASDAQ:AVDL) decreased 1.3% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 47.83% year over year to ($0.12), which missed the estimate of ($0.10).Revenue of $10,091,000 declined by 42.51% year over year, which beat the estimate of $7,370,000.Looking Ahead Avadel Pharmaceuticals hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on AVDLTime: 08:30 AMET Webcast URL: http://public.viavid.com/player/index.php?id=141026Recent Stock Performance Company's 52-week high was at $13.4952-week low: $1.82Price action over last quarter: down 9.64%Company Description Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.See more from Benzinga * Royal Caribbean Cruises: Q2 Earnings Insights * Motorcar Parts of America: Q1 Earnings Insights * LiqTech International: Q2 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/10/2020
|
Avadel Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Business Update
- * Presented positive topline data from the pivotal Phase 3 REST-ON study * Announced today that results of the data analyses for the secondary endpoints of the REST-ON study were consistent with the primary analyses and further demonstrated the overall statistical significance of FT218 compared to placebo * Completed the pre-NDA meeting for FT218 with the Food and Drug Administration * First patient dosed in the open-label extension/switch study of investigational once-nightly FT218 * Strengthened balance sheet through completion of $125 million public equity offering to support the company’s strategic priorities * Completed sale of the sterile injectable drug portfolio for $42.0 million * Management to host a conference call today at 8:30 a.m. ETDUBLIN, Ireland, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced its financial results for the second quarter ended June 30, 2020 and provided a company update.“We are at a pivotal point in Avadel’s transformation, as we recently completed our pre-NDA meeting with the FDA and are currently focused on completing our NDA submission and filing for FT218. A key component of the planned NDA for FT218 is the positive data from the Phase 3 REST-ON study of FT218, which was first announced in April. These data show that the three dose levels of FT218 that were tested demonstrated statistically significant (p<0.001) and clinically meaningful improvement for all three co-primary endpoints. In addition, FT218 was highly significant for the secondary endpoints that tested additional measures of daytime sleepiness, sleep architecture, and other narcolepsy symptoms compared to placebo at all three doses and all sensitivity analyses of the primary endpoint. If approved, FT218 could be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy,” said Greg Divis, Chief Executive Officer of Avadel.“In May, we strengthened our balance sheet with the completion of a public equity offering for gross proceeds of $125.0 million that will be used to support the development and plan for the go-to-market strategy of FT218. In June, we further bolstered our cash position with the sale of our legacy portfolio of sterile injectable drugs for $42.0 million. Divesting this product portfolio is in line with our overall strategy to focus the Company’s resources on FT218, thus streamlining and focusing Avadel while enabling the company to maintain optionality for creating shareholder value.”“As we move forward for the balance of 2020, our highest priority remains the completion and filing of our once-nightly FT218 NDA. In addition, we are in the process of compiling additional supporting scientific data to position FT218 in the market which includes the ongoing open-label extension (OLE)/switch study of FT218,” concluded Mr. Divis.Second quarter and recent company highlights * Presented an update on the development of FT218 and positive results from the Phase 3 Rest-On clinical trial for excessive daytime sleepiness and cataplexy in patients with narcolepsy, which were previously announced in April 2020:° FT218 at the 9 g dose demonstrated highly statistically significant (p<0.001) and clinically meaningful improvement across all three co-primary endpoints (Maintenance of Wakefulness Test, Clinical Global Impression-Improvement and Mean Weekly Cataplexy Attacks) compared to placebo. ° FT218 at the 9 g dose was generally well-tolerated, with commonly known sodium oxybate adverse reactions occurring at low rates (nausea 1.3%, vomiting 5.2%, decreased appetite 2.6%, dizziness 5.2%, somnolence 3.9%, tremor 1.3%, enuresis 9%; discontinuation rate due to adverse reactions 3.9%). ° FT218 at the 7.5 g and 6 g dose levels also achieved highly statistically significant (p<0.001), clinically meaningful improvements across all three co-primary endpoints compared to placebo, as soon as 3 weeks after initiating FT218. * Announced today additional data from the REST-ON study:° All three doses of FT218 studied were highly significant compared to placebo on secondary endpoints evaluating daytime sleepiness, sleep architecture, and other narcolepsy symptoms ° FT218 was also significant compared to placebo for all sensitivity analyses of the three co-primary endpoints at all three doses ° Detailed data for the secondary endpoints and sensitivity analyses will be presented at a scientific conference or in a peer-reviewed scientific publication * Held a successful pre-NDA meeting with the FDA and are on track to move forward with filing our NDA for FT218 * First patient dosed in an OLE/switch study of FT218 as a potential treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. * Completed a public equity offering with gross proceeds of $125.0 million to strengthen the Company’s balance sheet and provide capital to support its strategic priorities. * Completed the sale of the legacy portfolio of sterile injectable drugs used in the hospital setting to Exela Sterile Medicines LLC for a total of $42.0 million.Overview of Second Quarter Results Revenues for the second quarter of 2020 were $10.1 million, compared to $17.6 million in the second quarter of 2019. The decline on a year-over-year basis was primarily attributed to lower overall sales volume across the Company’s hospital products as a result of increased market competition.R&D expenses were $4.1 million in the second quarter of 2020, compared to $10.3 million in the second quarter of 2019. The decrease on a year-over-year basis was primarily attributed to the completion of the FT218 clinical study during the first quarter of 2020, as well as lower headcount due to the restructuring activities initiated during 2019. SG&A expenses were $7.1 million in the second quarter of 2020, compared to $6.8 million in the second quarter of 2019. The year-over-year increase is primarily the result of higher professional fees and market research costs related to FT218.A $45.8 million pre-tax gain from the sale of the portfolio of sterile injectable drugs was recorded in the second quarter of 2020. The gain reflects the $42.0 million transaction price adjusted for the net liabilities that were transferred to Exela Sterile Medicines LLC and transaction costs incurred by the company.Income tax provision was $5.3 million in the second quarter of 2020, compared to $1.8 million in the second quarter of 2019. Net income for the second quarter of 2020 was $30.9 million, or $0.49 per diluted share, compared to a net loss of $8.6 million, or ($0.23) per diluted share, for the same period in 2019. Cash, cash equivalents and marketable securities were $238.6 million as of June 30, 2020. The Company has convertible debt of $143.8 million due in February 2023.Conference Call: A conference call to discuss these results has been scheduled for Monday, August 10, 2020 at 8:30 a.m. ET. To access the conference call, investors are invited to dial (877) 407-9716 (U.S. and Canada) or (201) 493-6779 (International). The conference ID number is 13707645. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.About FT218 FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. In March of 2020, the Company completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.Cautionary Disclosure Regarding Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, the planned submission of the FT218 NDA to the FDA and commercial launch of FT218, if approved. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions, and the negatives thereof (if applicable).Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable.
- 08/10/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Oppenheimer: These 3 “Strong Buy” Stocks Could Double, If Not More
- The “dog days” of summer are here, but it’s just as busy as ever on the Street. As earnings results continue to roll in, investors will be watching for any update on the next economic stimulus package along with the non-farm payroll report slated for release this Friday. Against this backdrop, plenty of questions remain, weighing on the minds of both institutional and private investors.In a recent note to clients, Oppenheimer’s Chief Investment Strategist John Stoltzfus addresses these concerns. When it comes to stocks’ disconnected state, he writes that the market tends to focus on the future, with it betting on a successful outcome based on the stimulus policy already put in place. But will this highly accommodative monetary policy eventually cause inflation?“We do not expect high levels of inflation to result from the extraordinary stimulus and monetary policy taken to deal with the Covid-19 pandemic. Federal Reserve vigilance against inflation (as well as vigilance by central banks around the world) is likely to be able to suitably address any flare up of inflation,” Stoltzfus commented.Bearing this in mind, we took a closer look at three stocks backed by the analysts at Oppenheimer, the third best-performing research firm, according to TipRanks. Running the tickers through TipRanks’ database, we learned Oppenheimer sees at least 120% upside potential in store for each, and all three have earned a “Strong Buy” consensus rating from the rest of the Street.Durect Corporation (DRRX)Developing innovative therapies based on its endogenous epigenetic regulator program, Durect believes it could potentially transform the treatment of acute organ injury and chronic liver diseases. As one of its candidates has delivered encouraging results, Oppenheimer sees an opportunity to get in on the action.Firm analyst Francois Brisebois recently told clients, “After several years of promising results, we believe DRRX's endogenous small molecule epigenetic regulator DUR-928 has finally found its home in the treatment of Alcoholic Hepatitis (AH). Given a high level of mortality (26% 1-month rate) and no viable treatment options, we believe DUR-928's fairly early robust Phase 2a efficacy and safety data could have it attacking this ~ $3 billion market opportunity with peak penetration as early as 2025.”Digging a bit deeper into this Phase 2a data, along with a robust safety profile, the trial showed that the therapy was able to rapidly reduce bilirubin, a marker of AH. In addition, there was a 100% response to treatment from the Lille score (mortality predictor tool) in 30mg and 90mg dosages and reduction in MELD (AH severity). Going forward, AH Phase 2b is set to begin in 2H20. “Given the potential to receive Breakthrough Therapy Designation (BTD) for treating a life-threatening condition with a substantial improvement over available therapies (mainly corticosteroids), launch could happen ahead of anticipation. Additionally, market exclusivity and pricing could be greater if Orphan Drug Designation (ODD) is awarded based on ~117,000 annual hospitalizations,” Brisebois added.Plenty of other catalysts are still ahead, in Brisebois’ opinion. DUR-928 is being evaluated in hospitalized COVID-19 patients with acute liver or kidney injury in a Phase 2 study and Phase 1b NASH data could be released during an upcoming conference. It should also be noted that it’s a “waiting game” for Posimir’s PDUFA, with the analyst considering “any related weakness as a buying opportunity.”All of the above makes Brisebois optimistic about DRRX’s long-term growth prospects. As a result, the analyst continues to assign an Outperform rating and $7 price target to the stock. Should his thesis play out, a potential twelve-month gain of 202% could be in the cards. (To watch Brisebois’ track record, click here) Brisebois’ colleagues are also pounding the table on DRRX. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $6, the average price target implies shares could climb 156% higher in the next year. (See DRRX stock analysis on TipRanks)Avadel Pharmaceuticals (AVDL)Hoping to address overlooked and unmet medical needs, Avadel Pharmaceuticals wants to provide solutions through its patient-focused and cutting-edge products. With Oppenheimer stating its asset has “disruptive potential in a proven blockbuster market,” the firm believes it might be time to snap up shares. According to analyst Francois Brisebois, who also covers DRRX, AVDL is primarily focused on FT218, a once-nightly sodium oxybate designed for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. He goes so far as to call the candidate the company’s “first, second and third priorities,” noting that it recently sold its Hospital Drug Portfolio “to avoid distractions.”Looking at the pivotal Phase 3 REST-ON top-line data, Brisebois believes it “speaks for itself.” At the 9g dose, FT218 was able to produce a change from baseline in Maintenance of Wakefulness (MWT) of 10.82 minutes vs. 4.469 in placebo, in Clinical Global Impression-Improvement (CGI-I) of 72% vs. 31.6% and in Mean Weekly Cataplexy Attacks of -11.51 vs. -4.86, all three of the co-primary endpoints. “We were particularly impressed that the 6g and 7.5g doses also showed p<0.001 across all co-primary endpoints,” the analyst added.The implication? “Following strong efficacy and safety data, we believe FT218 could significantly disrupt Jazz Pharmaceuticals' Xyrem (twice-nightly sodium oxybate), which reported FY19 sales of $1.6 billion,” Brisebois said.While some investors have expressed concern regarding the company’s freedom to operate, Brisebois isn’t too worried. “We are comfortable with AVDL's freedom to operate path forward as we don't believe it will infringe on Xyrem's IP (REMS or DDI). Although FT218 does use the same drug substance, it consists of a substantially different drug product. The label should add more clarity,” he explained.Additionally, management has made a significant effort to drive a turnaround. Brisebois points out that since CEO Greg Divis was appointed in June 2019, he has offered clear guidance on enrollment, which has led to huge gains in the share price. He also mentioned, “Dr. Jordan Dubow's appointment as CMO was key because of his important role in adjusting the original study design (data a year ahead of expectations). New CFO Thomas McHugh's commercial experience is crucial.”Given everything that AVDL has going for it, it’s clear why Brisebois joined the bulls. In addition to initiating coverage with an Outperform rating, the analyst put a $19 price target on the stock. What does this mean for investors? Upside potential of 134% is at play.Overall, the bulls take the lead on this one. Out of 5 total reviews published in the last three months, all 5 analysts rated the stock a Buy. Therefore, the message is clear: AVDL is a Strong Buy. The $18.40 average price target implies shares could skyrocket 126% in the next twelve months. (See Avadel stock analysis on TipRanks)CymaBay Therapeutics (CBAY)Last but not least we have CymaBay Therapeutics, which develops therapies designed to improve the lives of patients with liver and other chronic diseases. Given its impressive technology, Oppenheimer has high hopes.Covering the stock for the firm, analyst Jay Olson points out that its seladelpar asset produced strong results in the ENHANCE Phase 3 study in PBC. As it was terminated early and there were only a small number of patients that reached 12 months, the primary endpoint was changed to 3 months. The revised primary composite and key secondary ALP normalization endpoints were both statistically significant at 10mg. “We believe these impressive efficacy results could set a new paradigm for physicians and patients as they strive to achieve ALP normalization,” the analyst commented.Going into more detail, 30% of patients in the study had moderate-to-severe pruritus, and the pruritus levels were balanced and representative of high-risk PBC patients, in Olson’s opinion. Unlike Ocaliva, which has a warning for severe pruritus with management strategies that include temporary dosing interruption, seladelpar was able to generate a substantial improvement in pruritus.Based on this promising data, CBAY could kick off a Phase 3 PBC study. “We expect CBAY to initiate this simplified Phase 3 PBC trial in 1Q21 with 12-month primary endpoint for pivotal data in 2023. The safety profile of seladelpar is similar to placebo and compares favorably to Ocaliva's which has a boxed warning for dosing in certain patients,” Olson stated.When it comes to the NASH indication, Phase 2b 52-week biopsy data, which showed a solid reduction in fibrosis and NASH resolution, could support seladelpar’s progression to Phase 3. It should be noted that CBAY might seek a partner here.With the company boasting a path forward in 2L PBC that could establish seladelpar as the standard of care, the deal is sealed for Olson. To this end, the analyst rates CBAY an Outperform (i.e. Buy) along with a $12 price target. This figure suggests 127.5% upside potential from current levels. (To watch Olson’s track record, click here) Looking at the consensus breakdown, other analysts echo Olson’s sentiment. With 8 Buys compared to no Holds or Sells, the word on the Street is that CBAY is a Strong Buy. In addition, the $12 average price target is identical to the Oppenheimer analyst’s. (See CBAY stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- 08/05/2020
|
Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2020
- Market forces rained on the parade of Avadel Pharmaceuticals plc (NASDAQ:AVDL) shareholders today, when the analysts...
- 08/01/2020
|
Harmony Biosciences Starts U.S. IPO Effort
- Harmony Biosciences has filed to raise $100 million in an IPO, although the final figure will likely differ.
- 07/31/2020
|
Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th
- DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2020. To access the conference call, investors are invited to dial 877-407-9716 (U.S. and Canada) or 201-493-6779 (international). The conference ID number is 13707645. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. For more information, please visit www.avadel.com.Contacts: Investor Contacts Tom McHugh Chief Financial Officer Phone: (636) 449-1843 Email: tmchugh@avadel.com Tim McCarthy LifeSci Advisors, LLC Phone: (212) 915.2564 Email: tim@lifesciadvisors.com Media Contact Patrick Bursey LifeSci Communications, LLC Phone: (646) 970-4688 Email: pbursey@lifescicomms.com
- 07/27/2020
|
Avadel Pharmaceuticals (NASDAQ:AVDL) Upgraded to Hold at BidaskClub
- Avadel Pharmaceuticals (NASDAQ:AVDL) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday, BidAskClub reports. A number of other research analysts have also recently weighed in on AVDL. Craig Hallum lifted their price target on shares of Avadel Pharmaceuticals from $18.00 to $13.50 in […]
- 07/20/2020
|
Zacks: Brokerages Anticipate Avadel Pharmaceuticals PLC (NASDAQ:AVDL) Will Post Earnings of -$0.16 Per Share
- Equities research analysts expect Avadel Pharmaceuticals PLC (NASDAQ:AVDL) to post earnings of ($0.16) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Avadel Pharmaceuticals’ earnings, with estimates ranging from ($0.22) to ($0.10). Avadel Pharmaceuticals reported earnings per share of ($0.23) in the same quarter last year, which […]
- 07/16/2020
|
Assessing An Investment In Avadel Pharmaceuticals
- Today, we take an in-depth look at Avadel Pharmaceuticals which recently sold off its existing product portfolio.
- 07/16/2020
|
Equillium COVID-19 Data, And Other News: The Good, Bad And Ugly Of Biopharma
- Equillium reports positive data for COVID-19 drug trial. CytoDyn's BLA filing is rejected.
- 07/15/2020
|
Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
- Clinical study to enroll 250 patients from sites that participated in the REST-ON studyStudy to examine the long-term safety and maintenance of efficacy in patients, and.
- 07/13/2020
|
Jazz Pharmaceuticals: Buy, Sell, Or Hold (NASDAQ:JAZZ)
- Jazz Pharmaceuticals plc is trading at 9x revised 2020E Adj. EPS after dropping ~30% since mid-January.
- 07/09/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avadel Pharmaceuticals
- 07/08/2020
|
Avadel Pharmaceuticals (AVDL) Gets a Buy Rating from LifeSci Capital - Markets
- LifeSci Capital analyst David Sherman maintained a Buy rating on Avadel Pharmaceuticals (AVDL – Research Report) on July 1 and
- 07/05/2020
|
Bearish: Analysts Just Cut Their Avadel Pharmaceuticals plc (NASDAQ:AVDL) Revenue and EPS estimates
- Market forces rained on the parade of Avadel Pharmaceuticals plc (NASDAQ:AVDL) shareholders today, when the analysts...
- 07/03/2020
|
H.C. Wainwright Thinks Zynerba Pharmaceuticals' Stock is Going to Recover - Markets
- H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report) today and set a
- 07/01/2020
|
Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million
- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™, which is approved by the U.S. Food and Drug Administration, to Exela Sterile Medicines LLC for a total of $42.0 million. “The sale of the sterile injectable drug portfolio is a significant milestone for the Company, as it further reflects our commitment to strategically focus on advancing FT218 through the regulatory review process and, if approved, bringing our once-nightly formulation of sodium oxybate to patients,” said Greg Divis, Chief Executive Officer of Avadel.
- 07/01/2020
|
Analysts Are Bullish on These Healthcare Stocks: Sol-Gel Technologies (SLGL), Seattle Genetics (SGEN) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sol-Gel Technologies
- 06/30/2020
|
Pot Slump Creates Distressed Opportunities: Cannabis Weekly - BNN Bloomberg
- Cannabis stocks have lost about a quarter of their value in the first half of 2020, compounding a 50% drop in 2019.
- 06/28/2020
|
Pot Slump Creates Distressed Opportunities: Cannabis Weekly
- (Bloomberg) — Cannabis stocks have lost about a quarter of their value in the first half of 2020, compounding a 50% drop in 2019.The upside for investors? There’s never been a better ti…
- 06/28/2020
|
Hedge Funds Have Never Been More Bullish On Avadel Pharmaceuticals plc (AVDL)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 06/28/2020
|
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) Expected to Post Earnings of -$0.14 Per Share
- Wall Street brokerages expect Avadel Pharmaceuticals PLC (NASDAQ:AVDL) to announce ($0.14) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Avadel Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.21) and the highest estimate coming in at ($0.10). Avadel Pharmaceuticals reported earnings of ($0.23) per share during […]
- 06/24/2020
|
Supernus Pharmaceuticals (SUPN) Got Some Good News - Markets
- In a report released today, David Amsellem from Piper Sandler upgraded Supernus Pharmaceuticals (SUPN – Research Report) to Buy, with
- 06/16/2020
|
Avadel Pharmaceuticals to Present at BIO Digital
- DUBLIN, Ireland, June 08, 2020 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium.
- 06/08/2020
|
Jazz Pharmaceuticals: Pandemic Leaves The Leading Drug In A Catch 22 (NASDAQ:JAZZ)
- As the pandemic fears squeeze the new patient enrollments for Xyrem, JAZZ has downgraded the revenue guidance. While the economic downturn stifles the revenue g
- 06/01/2020
|
How Avadel (AVDL) Stock Stands Out in a Strong Industry
- Avadel (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/01/2020
|
Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
- DUBLIN, Ireland, June 01, 2020 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium.
- 06/01/2020
|
2 Top Healthcare Stocks to Buy Right Now
- One is a blue chip, the other a small-cap, but both are innovators with significant growth opportunities.
- 05/28/2020
|
Coronavirus Impact on Healthcare Acquired Infection Market
- May 26, 2020 (Heraldkeepers) --
New York, May 26, 2020: You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports...
- 05/26/2020
|
Avadel Pharmaceuticals plc (AVDL) Q1 2020 Earnings Call Transcript
- It is now my pleasure to introduce your host Tom McHugh, Chief Financial Officer. As a reminder before we begin the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
- 05/11/2020
|
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2020 Results - Earnings Call Transcript
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2020 Earnings Conference Call May 11, 2020 08:30 AM ET Company Participants Thomas McHugh - Chief Financial Officer
- 05/11/2020
|
Avadel (AVDL) Beats on Earnings & Revenue Estimates in Q1
- Avadel's (AVDL) first quarter 2020 earnings and revenues surpass expectations.
- 05/11/2020
|
Strongbridge Biopharma: Attractive Valuation With Catalysts Approaching
- SBBP shares continue to be significantly discounted relative to the opportunity for Recorlev as a treatment for Cushing's Syndrome. Peak revenue estimates for R
- 05/11/2020
|
Avadel Pharmaceuticals Reports First Quarter 2020 Financial Results
- Reported positive topline data from the pivotal Phase 3 REST-ON studyStrengthened balance sheet with $190 million in gross proceeds from a private placement in February 2020 and.
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Why Jazz Pharmaceuticals' Symphony of Growth Is About to End
- Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.
- 05/09/2020
|
Jazz Pharmaceuticals (JAZZ) Q1 2020 Earnings Call Transcript
- JAZZ earnings call for the period ending March 31, 2020.
- 05/06/2020
|
Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th
- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 11, 2020, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2020. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. Avadel Pharmaceuticals plc (AVDL) is an emerging biopharmaceutical company.
- 05/04/2020
|
U.S. RESEARCH ROUNDUP-Berkshire Hathaway, DHT Holdings, Novo Nordisk
- Wall Street securities analysts revised their ratings and price targets on several
U.S.-listed companies, including Berkshire Hathaway, DHT Holdings and Novo Nordisk, on Monday.
HIGHLIGHTS
* Berkshire Hathaway Inc : KBW raises target price to $325,000 from $310,000
* CyrusOne Inc : Jefferies raises to buy from hold
* DHT Holdings Inc : Evercore ISI cuts to in line from outperform
* Frontline Ltd : Evercore ISI cuts to in line from outperform
* Novo Nordisk : Cowen and Company initiates with market perform, $72 target price
Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in
alphabetical order.
* 2U Inc : Barrington Research raises price target to $30 from $25
* Abbvie Inc : Mizuho raises target price to $101 from $100
* Abbvie Inc : RBC raises price target to $98 from $93
* Abbvie Inc : SVB Leerink raises target price to $107 from $103
* Activision Blizzard Inc : Credit Suisse raises target price to $79 from $69
* Allegiance Bancshares Inc : KBW raises target price to $32 from $31
* Allscripts Healthcare Solutions Inc : Cowen and Company cuts PT to $8 from $15
* Alteryx Inc : Rosenblatt Securities cuts price target to $115 from $145
* Amarin Corporation Plc : SVB Leerink raises target price to $9 from $7
* Amazon.Com Inc : Independent Research raises PT to $2900 from $2400; rating buy
* American Airlines : Citigroup cuts price target to $9 from $10
* American Tower Corp : Citigroup cuts price target to $266 from $280
* American Tower Corp : RBC raises target price to $261 from $240
* Angi Homeservices Inc : SunTrust Robinson cuts target price to $10 from $14
* Antero Midstream Corp : Citigroup cuts to neutral from buy; cuts PT to $4 from $7
* Apollo Global Management Inc : BMO raises target price to $43 from $39
* Apollo Global Management Inc : Citigroup cuts price target to $55 from $61
* Apollo Global Management Inc : Credit Suisse cuts target price to $44 from $45
* Apollo Global Management Inc : Evercore ISI raises target price to $43 from $41
* Apollo Global Management Inc : Jefferies raises target price to $45 from $44
* Apollo Global Management Inc : KBW cuts target price to $47 from $49
* Apollo Investment Corp : SunTrust Robinson cuts target price to $12 from $19
* Ardmore Shipping Corp : Evercore ISI cuts target price to $10 from $11
* Ares Capital Corp : SunTrust Robinson cuts target price to $15 from $20
* Arthur J Gallagher & Co : KBW cuts target price to $97 from $100
* Asgn Inc : BMO raises target price to $66 from $51
* Avadel Pharmaceuticals Plc : Piper Sandler raises target price to $18 from $14
* Bain Capital Specialty Finance Inc : Credit Suisse cuts PT to $15.50 from $20.50
* Balchem Corp : H.C. Wainwright cuts price target to $104 from $116
* Bank of America Corp : UBS raises price target to $21 from $20
* Bank of N.T. Butterfield & Son Ltd : KBW raises target price to $28 from $24
* Bank of N.T. Butterfield & Son Ltd : Raymond James raises PT to $24 from $20
* Bank7 Corp : Piper Sandler raises target price to $12 from $11
* Barings BDC Inc : Compass Point raises to buy from neutral
* Barings BDC Inc : KBW cuts target price to $8 from $8.5
* Bcb Bancorp Inc : D.A. Davidson cuts target price to $10 from $11
* Berkshire Hathaway Inc : KBW raises target price to $325,000 from $310,000
* Berkshire Hathaway Inc : UBS cuts target price to $350000 from $358000
* Berry Global Group Inc : Citigroup raises price target to $47 from $42
* Beyond Meat Inc : Jefferies raises target price to $83 from $72
* Big Lots Inc : Talsey Advisory Group raises to outperform from market perform
* Big Lots Inc : Telsey Advisory Group raises price target to $31 from $20
* Biomarin Pharmaceutical Inc : Wedbush cuts target price to $145 from $164
* Black Diamond Therapeutics Inc : HC Wainwright initiates at rating buy and $53 PT
* Bloomin' Brands Inc : MKM Partners raises target price to $13 from $11
* Booking Holdings Inc : Credit Suisse cuts target price to $1,790 from $1,870
* Brigham Minerals Inc : SunTrust Robinson cuts target price to $16 from $19
* Brookline Bancorp Inc : KBW cuts target price to $11 from $12
* Brooks Automation Inc : Stephens raises target price to $40 from $37
* Brunswick Corp : BMO raises target price to $37 from $34
* Brunswick Corp : Keybanc raises target price to $52 from $47
* Builders Firstsource Inc : Barclays raises target price to $19 from $16
* Builders Firstsource Inc : Benchmark cuts target price to $22 from $32
* Builders Firstsource Inc : BTIG cuts target price to $23 from $31
* Builders Firstsource Inc : D.A. Davidson raises target price to $22 from $20
* Builders Firstsource Inc : Evercore ISI raises target price to $21 from $15
* Builders Firstsource Inc : RBC raises target price to $20 from $15
* Builders Firstsource Inc : Stifel raises price target to $21 from $18
* Builders Firstsource Inc : SunTrust Robinson raises target price to $20 from $17
* Builders Firstsource Inc : Wedbush raises target price to $23 from $19
* Cabot Oil & Gas Corp : Piper Sandler cuts target price to $21 from $22
* Cabot Oil & Gas Corp : Susquehanna raises target price to $24 from $23
* Caci International Inc : JP Morgan raises target price to $270 from $220
* Callon Petroleum Co : Tudor Pickering Holt cuts to sell from hold
* Camping World Holdings Inc : Jefferies cuts target price to $8 from $12
* Carlyle Group Inc : Citigroup cuts price target to $33 from $34
* Carter Bank and Trust : Raymond James cuts target price to $10 from $13
* Carter'S Inc : Monness Crespi Hardt cuts target price to $100 from $115
* Charter Communications Inc : Cowen and Company raises PT to $597 from $593
* Charter Communications Inc : JP Morgan raises target price to $575 from $550
* Charter Communications Inc : Keybanc raises target price to $604 from $576
* Charter Communications Inc : Rosenblatt Securities raises PT to $620 from $600
* Charter Communications Inc : TD Securities raises price target to $560 from $515
* Cheniere Energy Inc : Scotiabank raises target price to $68 from $67
* Cheniere Energy Partners LP : Scotiabank raises target price to $33 from $32
* Chevron Corp : Citigroup raises price target to $85 from $65
* Chevron Corp : Cowen and Company raises target price to $90 from $88
* Chevron Corp : Credit Suisse raises target price to $100 from $81
* Chevron Corp : Jefferies raises target price to $100 from $90
* Chevron Corp : JP Morgan raises target price to $103 from $97
* Choice Hotels International Inc : UBS cuts price target to $89 from $100
* Choice Hotels International Inc : UBS raises to buy from neutral
* Cigna Corp : Bernstein cuts to market-perform from outperform
* Cigna Corp : Raymond James raises target price to $240 from $210
* Citigroup Inc : UBS raises price target to $64 from $50
* Citizens Financial Group Inc : UBS raises price target to $26 from $18
* Citizens Financial Group Inc : UBS raises to buy from neutral
* Clorox Co : Citigroup raises price target to $206 from $182
* Clorox Co : Credit Suisse raises target price to $180 from $172
* Clorox Co : UBS raises price target to $168 from $155
* CNX Midstream Partners LP : Citigroup cuts price target to $8 from $17
* CNX Midstream Partners LP : Citigroup cuts to neutral from buy
* Coastal Financial Corp (Everett) : KBW raises target price to $16 from $15
* Cognex Corp : Berenberg raises target price to $60 from $52
* Cognizant Technology Solutions Corp : BMO cuts to market perform from outperform
* Cognizant Technology Solutions Corp : BMO raises target price to $59 from $58
* Colgate-Palmolive Co : Citigroup cuts price target to $75 from $78
* Colgate-Palmolive Co : Stifel raises price target to $75 from $72
* Columbia Banking System Inc : KBW cuts target price to $34 from $37
* Community Bankers Trust Corp : Stephens cuts target price to $7.50 from $9
* Community Health Systems Inc : Oppenheimer cuts target price to $7 from $8
* Concho Resources Inc : MKM Partners cuts price target by $5 to $75
* Concho Resources Inc : Simmons Energy raises target price to $59 from $54
* Concho Resources Inc : TD Securities raises price target to $53 from $49
* Conocophillips : MKM Partners raises target price by $1 to $58
* Consolidated Communications Holdings Inc : Citigroup raises PT to $6 from $5
* Consolidated Communications Holdings Inc : Guggenheim raises PT to $4 from $3.
- 05/04/2020
|
Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More
- Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat
- 05/01/2020
|
Avadel Pharmaceuticals Announces Pricing of Public Offering
- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today the pricing of an underwritten public offering of 11,630,000 ordinary shares, in the form of American Depositary Shares (“ADSs”) at a price to the public of $10.75 per ADS. All of the ADSs are being offered by Avadel. In connection with the public offering, Avadel has granted the underwriters a 30-day option to purchase up to an additional 1,744,500 ADSs at the public offering price less the underwriting discounts and commissions.
- 04/29/2020
|
6 Stocks To Watch: AMC, BLDR, CREX, KURA, NGL, RRGB
- Stocks Analysis by Harry Boxer covering: MGM Resorts International, Fluor Corporation, Builders FirstSource Inc, Avadel Pharmaceuticals PLC. Read Harry Boxer's latest article on Investing.com
- 04/29/2020
|
Is a Beat in Store for Avadel (AVDL) This Earnings Season?
- On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.
- 04/28/2020
|
Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy?
- Will a small change in a drug's method of delivery be enough to generate over $1 billion in new sales?
- 04/28/2020
|
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Avadel Pharmaceuticals PLC
- 04/28/2020
|
Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering
- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it is commencing an underwritten public offering of $100 million in ordinary shares, in the form of American Depositary Shares (“ADSs”). All of the ADSs are being offered by Avadel. In connection with the offering, Avadel intends to grant the underwriters a 30-day option to purchase up to an additional $15 million in ADSs at the public offering price less the underwriting discounts and commissions.
- 04/27/2020
|
This Top-Ranked Biotech Stock Touched A 4-Year High — Here's Why
- Avadel Pharmaceuticals stock rocketed Monday after the biotech company said its narcolepsy treatment succeeded in a Phase 3 test. The drug is a once-nightly form of sodium oxybate.
- 04/27/2020
|
Why Avadel Pharmaceuticals Stock Is Crushing It Today
- Investors are excited about positive late-stage results for its narcolepsy drug.
- 04/27/2020
|
A Look Into Avadel Pharmaceuticals' Price Over Earnings
- In the current session, Avadel Pharmaceuticals Inc. (NASDAQ: AVDL) is trading at $12.95, after a 31.74% increase. Over the past month, the stock increased by 63.60%, and in the past year, by 939.20%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently above from its 52 week high by 20.47%.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P; 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 7.57 in the specialty & generic drug manufacturers industry, Avadel Pharmaceuticals has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may be unable to attain key insights from trailing earnings.See more from Benzinga * Morning Market Stats in 5 Minutes * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 04/27/2020
|
Morning Market Stats in 5 Minutes
- Movers Indices • S&P 500 ETF (NYSE:SPY) rose 0.78% to $285.09.• Nasdaq ETF (NASDAQ:QQQ) increased 1.06% to $216.10.• Dow Jones Industrial Average ETF (NYSE:DIA) increased 0.49% to $238.96.• FTSE/Xinhua China 25 ETF (NYSE:FXI) increased 1.28% to $38.65.• FTSE Europe ETF (NYSE:VGK) rose 0.60% to $44.95
- 04/27/2020
|
Stocks That Hit 52-Week Highs On Monday
- During Monday's morning session, these companies made new 52-week highs.
Noteworthy Points:
The largest company by market cap to set a new 52-week high was Novo Nordisk...
- 04/27/2020
|
AMRN, EPR among top gainers
- Axsome Therapeutics (NASDAQ:AXSM) +44% as Axsome's lead candidate successful in Alzheimer's study.Avadel Pharmaceuticals plc (NASDAQ:AVDL) +34% on positive data on lead drug.Yield10 Bioscience (NASDAQ
- 04/27/2020
|
Avadel up 30% premarket on positive data on lead drug
- Avadel Pharmaceuticals (NASDAQ:AVDL) jumps 30% premarket on average volume in reaction to positive results from a Phase 3 clinical trial, REST-ON, evaluating lead candidate FT218, a once-nightly formu
- 04/27/2020
|
Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
- The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically significant (p<0.001), and clinically meaningful improvement across all.
- 04/27/2020
|
Jefferies sees 93% upside in Avadel Pharma in premarket analyst action
- Arcus Biosciences (NYSE:RCUS) initiated with an Overweight rating and a $21 (41% upside) price target at Cantor Fitzgerald.Avadel Pharmaceuticals (NASDAQ:AVDL) initiated with a Buy rating and a $14 (9
- 04/03/2020
|
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance
- The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
- 03/26/2020
|
Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it has completed the REST-ON Phase 3 clinical trial for FT218. The REST-ON study enrolled a total of 212 patients, and the last patient last visit occurred earlier this week. The Company currently expects to announce topline data from the study in the second quarter of 2020.
- 03/25/2020
|
Avadel Pharmaceuticals plc Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
- Shareholders in Avadel Pharmaceuticals plc (NASDAQ:AVDL) had a terrible week, as shares crashed 39% to US$6.01 in the...
- 03/14/2020
|
Does Market Volatility Impact Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Share Price?
- If you own shares in Avadel Pharmaceuticals plc (NASDAQ:AVDL) then it's worth thinking about how it contributes to the...
- 03/13/2020
|
Baird cuts view on Teladoc in premarket analyst action
- Allakos (NASDAQ:ALLK) initiated with Underperform rating and $34 (42% downside risk) price target at SMBC Nikko.Avadel Pharmaceuticals (NASDAQ:AVDL) initiated with Buy rating and $14 (75% upside) pric
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacted to its fourth-quarter results) * Centogene NV (NASDAQ: CNTG) * Tiziana Life Sciences PLC (NASDAQ
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news. View more earnings on IBBThe following are key catalysts in the unfolding week that a biotech
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
Best & Worst ADRs - Tuesday, March 3
- The top-ranked sectors are healthcare, utilities, and technology. Services are neutral.
- 03/03/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
- 02/25/2020
|
6 Stock Charts To Watch: EGO, GILD, LAKE, SURF, TVIX, ZYXI6
- Stocks Analysis by Harry Boxer covering: Gilead Sciences Inc, Lakeland Industries Inc, Eldorado Gold Corp, ProShares Ultra VIX Short-Term Futures ETF. Read Harry Boxer's latest article on Investing.com
- 02/25/2020
|
94 Biggest Movers From Friday
- Gainers
Trans World Entertainment Corporation (NASDAQ: TWMC) shares jumped 50.9% to close at $5.28 on Friday after the company disclosed that its subsidiary etailz entered into a...
- 02/24/2020
|
3 Biotech Stocks That Soared This Week: Are They Buys?
- Can these high-flying biotech stocks keep up their sizzling momentum?
- 02/22/2020
|
How a Small-Cap Fund Finds Exceptional Growth Overseas
- The Brown Capital Management International Small Company fund has outperformed peers and its benchmark over the past three years. Its secret is focusing on a company’s revenue growth to identify winning stocks.
- 02/12/2020
|
Strongbridge Biopharma: A Big Opportunity For Cushing's Syndrome Patients And For Investors
- A major catalyst is approaching for SBBP with Phase 3 results for lead value driver, Recorlev, expected in 2Q or 3Q. Recorlev’s first Phase 3 trial, SONICS, had
- 01/30/2020
|
